title: Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat.
abstract: The selective serotonin reuptake inhibitor (SSRI) Prozac® (fluoxetine) is the only registered antidepressant to treat depression in children and adolescents. Yet, while the safety of SSRIs has been well established in adults, serotonin exerts neurotrophic actions in the developing brain and thereby may have harmful effects in adolescents. Here we treated adolescent and adult rats chronically with fluoxetine (12 mg/kg) at postnatal day (PND) 25 to 46 and from PND 67 to 88, respectively, and tested the animals 7-14 days after the last injection when (nor)fluoxetine in blood plasma had been washed out, as determined by HPLC. Plasma (nor)fluoxetine levels were also measured 5 hrs after the last fluoxetine injection, and matched clinical levels. Adolescent rats displayed increased behavioral despair in the forced swim test, which was not seen in adult fluoxetine treated rats. In addition, beneficial effects of fluoxetine on wakefulness as measured by electroencephalography in adults was not seen in adolescent rats, and age-dependent effects on the acoustic startle response and prepulse inhibition were observed. On the other hand, adolescent rats showed resilience to the anorexic effects of fluoxetine. Exploratory behavior in the open field test was not affected by fluoxetine treatment, but anxiety levels in the elevated plus maze test were increased in both adolescent and adult fluoxetine treated rats. Finally, in the amygdala, but not the dorsal raphe nucleus and medial prefrontal cortex, the number of PSA-NCAM (marker for synaptic remodeling) immunoreactive neurons was increased in adolescent rats, and decreased in adult rats, as a consequence of chronic fluoxetine treatment. No fluoxetine-induced changes in 5-HT(1A) receptor immunoreactivity were observed. In conclusion, we show that fluoxetine exerts both harmful and beneficial age-dependent effects on depressive behavior, body weight and wakefulness, which may relate, in part, to differential fluoxetine-induced neuroplasticity in the amygdala.
authors.affiliation: Department of Cognitive Neuroscience, Centre for Neuroscience, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. j.homberg@cns.umcn.nl
authors.forename: Judith R
authors.initials: JR
authors.lastname: Homberg
authors.forename: Jocelien D A
authors.initials: JD
authors.lastname: Olivier
authors.forename: Tom
authors.initials: T
authors.lastname: Blom
authors.forename: Tim
authors.initials: T
authors.lastname: Arentsen
authors.forename: Chantal
authors.initials: C
authors.lastname: van Brunschot
authors.forename: Pieter
authors.initials: P
authors.lastname: Schipper
authors.forename: Gerdien
authors.initials: G
authors.lastname: Korte-Bouws
authors.forename: Gilles
authors.initials: G
authors.lastname: van Luijtelaar
authors.forename: Liesbeth
authors.initials: L
authors.lastname: Reneman
mesh_terms: D000367:Age Factors; D000679:Amygdala / Q000187:drug effects* / Q000502:physiology; D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D003863:Depression / Q000188:drug therapy; D003866:Depressive Disorder / Q000188:drug therapy; D005473:Fluoxetine / Q000494:pharmacology*; D009473:Neuronal Plasticity / Q000187:drug effects*; D051381:Rats; D014851:Wakefulness / Q000187:drug effects
chemical_list: D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine